Literature DB >> 8497849

Distribution of tissue factor pathway inhibitor in normal and malignant human tissues.

R W Werling1, L R Zacharski, W Kisiel, S P Bajaj, V A Memoli, S M Rousseau.   

Abstract

Specific antibodies to tissue factor pathway inhibitor (TFPI) were used in immunohistochemical procedures to determine the distribution of TFPI in normal and neoplastic human tissues. TFPI was restricted to megakaryocytes and the endothelium of the microvasculature in normal and abnormal tissues, but was not found in the endothelium of larger vessels or in hepatocytes. TFPI was also detected in macrophages in the villi of term placenta. Tumor-associated macrophages in several types of malignancy that we have shown previously to express a complete tissue factor-initiated pathway of coagulation and thrombin generation also manifested TFPI. By contrast, malignant cells in small cell carcinoma of the lung, renal cell carcinoma, and malignant melanoma that we have shown previously to express coagulation factors together with tumor cell-associated fibrin formation failed to stain for TFPI. We postulate that TFPI may be lacking from the latter malignancies because of the absence of the appropriately configured tissue factor-factor VIIa-factor Xa complex required for TFPI binding.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8497849

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  20 in total

1.  Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion.

Authors:  S D Konduri; A Tasiou; N Chandrasekar; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells.

Authors:  M A Kurer
Journal:  Mol Biol Rep       Date:  2006-12-19       Impact factor: 2.316

3.  Endogenous tissue factor pathway inhibitor in vascular smooth muscle cells inhibits arterial thrombosis.

Authors:  Jichun Yang; Kaiyue Jin; Jiajun Xiao; Jing Ma; Duan Ma
Journal:  Front Med       Date:  2017-05-27       Impact factor: 4.592

4.  Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits.

Authors:  J H Erlich; J Apostolopoulos; T C Wun; K K Kretzmer; S R Holdsworth; P G Tipping
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

5.  Active tissue factor pathway inhibitor is expressed on the surface of coated platelets.

Authors:  Susan A Maroney; Sandra L Haberichter; Paul Friese; Maureen L Collins; Josephine P Ferrel; George L Dale; Alan E Mast
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

Review 6.  Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  World J Clin Oncol       Date:  2014-12-10

7.  Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development.

Authors:  Shuchong Pan; Thomas A White; Tyra A Witt; Anca Chiriac; Cheri S Mueske; Robert D Simari
Journal:  Circ Res       Date:  2009-08-27       Impact factor: 17.367

8.  Murine strain differences in hemostasis and thrombosis and tissue factor pathway inhibitor.

Authors:  Thomas A White; Shuchong Pan; Tyra A Witt; Robert D Simari
Journal:  Thromb Res       Date:  2009-04-26       Impact factor: 3.944

Review 9.  Hemostatic changes in patients with brain tumors.

Authors:  L Thoron; E Arbit
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 10.  Platelet tissue factor pathway inhibitor modulates intravascular coagulation.

Authors:  Susan A Maroney; Alan E Mast
Journal:  Thromb Res       Date:  2012-03-17       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.